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background: Breast cancer is the most common cancer in women in developed countries, and 12% of breast cancer occurs in women
20–34 years. Survival from breast cancer has signiﬁcantly improved, and the potential late effects of treatment and the impact on quality of
life have become increasingly important. Young women constitute a minority of breast cancer patients, but commonly have distinct concerns
and issues compared with older women, including queries regarding fertility, contraception and pregnancy. Further, they are more likely than
older women to have questions regarding potential side effects of therapy and risk of relapse or a new primary. In addition, many will have
symptoms associated with treatment and they present a management challenge. Reproductive medicine specialists and gynaecologists com-
monly see these women either shortly after initial diagnosis or following adjuvant therapy and should be aware of current management of
breast cancer, the options for women at increased genetic risk, the prognosis of patients with early stage breast cancer and how adjuvant
systemic treatments may impact reproductive function.
methods: No systematic literature search was done. The review focuses on the current management of breast cancer in young women
and the impact of treatment on reproductive function and subsequent management. With reference to key studies and meta-analyses, we
highlight controversies and current unanswered questions regarding patient management.
results: Chemotherapy for breast cancer is likely to negatively impact on reproductive function. A number of interventions are available
which may increase the likelihood of future successful pregnancy, but the relative safety of these interventions is not well established. For
those who do conceive following breast cancer, there is no good evidence that pregnancy is detrimental to survival. We review current
treatment; effects on reproductive function; preservation of fertility; contraception; pregnancy; breastfeeding and management of menopau-
sal symptoms following breast cancer.
conclusion: This paper provides an update on the management of breast cancer in young women and is targeted at reproductive
medicine specialists and gynaecologists.
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Breast cancer affects up to one in eight women in developed countries
with a median age of 61 years at diagnosis (www.cancer.org). The inci-
dence of breast cancer by age is shown in Table I. Approximately 2%
of breast cancers occur in young women between 20 and 34 years of
age and 11% between 35 and 44 years of age, which translates into
over 1500 women under 45 each year in Australia. These women
present unique and speciﬁc management issues and they are the
focus of this review (Ries et al., 2008).
Survival following breast cancer is improving, with over 88% of
patients alive at 5 years (Ries et al., 2008) although the prognosis
appears to be worse in young women under 35 years at diagnosis
(Aebi et al., 2000). In the USA, around 3 million women are survivors
of breast cancer, and this number is likely to increase with earlier diag-
nosis and improvements in adjuvant therapy (Ganz and Hahn, 2008).
Breast cancer survivors may present to the reproductive medicine
specialist and gynaecologist with a range of queries and symptoms,
and younger women have additional concerns particularly regarding
fertility and premature menopause that need to be addressed and
managed (Partridge et al., 2007). Clinicians who do not specialize in
breast cancer, but who nevertheless see these younger women for
advice regarding fertility and the gynaecological consequences of adju-
vant treatment should have a clear understanding of the current man-
agement of breast cancer, the common gynaecological complications
of treatment and the evidence regarding their optimal management.
In particular, the potential impact of fertility treatments on
hormone-receptor positive breast cancer needs to be considered
and discussed. In addition, the reproductive medicine specialist and
gynaecologist should be aware of current protocols for counselling,
surveillance and management of women who carry genetic mutations
which may increase their risk for breast, endometrial and ovarian
cancer. The majority of breast cancers are diagnosed at an early
stage, which is deﬁned as cancers that are potentially curable and
have not spread beyond the breast or the axillary lymph nodes
(ductal carcinoma in situ and stages I, IIA, IIB and IIIA).
Methods
No systematic literature search was done. This review focuses on early
breast cancer in young women by providing a brief overview and
summary of breast cancer management with reference to some key
studies and meta-analyses. We highlight the controversies and current
unanswered questions regarding patient management.
Current treatment of breast
cancer
Surgical management
Level 1 evidence from large randomized controlled trials (RCT) and
meta-analyses demonstrate equivalent survival rates with breast con-
serving therapy (BCT) and radiotherapy (RT) compared with mastect-
omy in women with early breast cancer (Early Breast Cancer Trialists’
Collaborative Group, 1995; Jatoi and Proschan, 2005; Yang et al.,
2008). Mastectomy is usually advised in patients at increased risk of
loco-regional recurrence (in the breast or draining lymph nodes)
with BCT and these risk factors include larger tumour size, multi-
centricity, an extensive intra-ductal component or extensive lympho-
vascular invasion (Newman and Kuerer, 2005; Schwartz et al., 2006;
White et al., 2008). Young age is also a risk factor for loco-regional
recurrence, and the place of BCT in young women, particularly
those ,35 years old is controversial as they appear to be at higher
risk of local recurrence than older women (Kim et al., 1998; Voogd
et al., 2001; Arriagada et al., 2003; Zhou and Recht, 2004; Schwartz
et al., 2006). BCT is the standard of care for early breast cancer,
and is unlikely to compromise survival in young women (Kroman
et al., 2004). However, the relative risks and beneﬁts of BCT versus
mastectomy in very young women remain uncertain since this popu-
lation has not been well represented in large RCT. In addition, as
up to 10% of very young women (Malone et al., 2000) may have an
inherited predisposition to breast cancer (even in the absence of a
family history), unilateral or bilateral mastectomy may be a good
option.
Reconstructive surgery should be offered to most women after
mastectomy. This is either via an implant placed under the skin and
pectoral muscles or using myocutaneous tissue transfer such as a latis-
simus dorsi or transverse rectus myocutaneous ﬂaps. These will not
impede the ability to detect recurrent disease, and although a
woman does not require imaging follow-up of the reconstructed
breasts, clinical examination is important to exclude local recurrence.
Axillary node dissection and sentinel
node biopsy
The clinical management of the axilla in women with early breast
cancer has changed radically over the last decade. Axillary node
dissection is associated with morbidity including lymphoedema in
10–20% of patients as well as sensory loss and restricted shoulder
movement (Mansel et al., 2006; Schulze et al., 2006; Del Bianco
et al., 2008). Over two-thirds of women have negative axillary
nodes and therefore have a potentially unnecessary surgical pro-
cedure. Sentinel node biopsy (SNB) is a minimally invasive surgical
technique to assess nodal involvement using blue dye and/or radioiso-
tope mapping to identify and map the location of sentinel nodes that
drain the breast. It is appropriate for women with smaller (,3 cm)
tumours that are unifocal. Axillary dissection is only required in
those patients with an involved or positive SNB. The false-negative
........................................................................................
Table I Incidence of breast cancer by age
Age Annual incidence/100000 women
,20 0.1
20–24 1.4
25–29 8.1
30–34 24.8
35–39 58.4
40–44 116.1
45–49 198.5
Reproduced from Future Oncol 2007;3(5):569–574 with permission of Future Medicine
Ltd. and the authors Pagani and Goldhirsch (2006).
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recurrences is very low—,1% in women who have been staged
with SNB (Naik et al., 2004). The procedure has signiﬁcantly less mor-
bidity than axillary node dissection and is associated with an improved
quality of life with no adverse impact on survival (Veronesi et al., 2006;
Krag et al., 2007).
Radiotherapy
RT signiﬁcantly reduces loco-regional recurrence which is associated
with increased morbidity and potentially increased mortality. RT is
recommended to all women after BCT and signiﬁcantly reduces
local recurrence from about 26% without radiation to 7% with radi-
ation (Clarke et al., 2005). There is evidence that a radiation boost
to the tumour bed is of beneﬁt in young women and further
reduces the risk of local recurrence after BCT (Vrieling et al., 2003).
Radiation is also advised following mastectomy to all patients who
have a high risk of local relapse, including those with tumours
.5 cm and/or those with at least four positive nodes or extensive
lymphovascular permeation (Overgaard et al., 1997; Ragaz et al.,
2005; Gebski et al., 2006). The role of RT in women with 1–3
involved axillary nodes is currently being addressed in clinical trials,
but there is evidence to support its role particularly in higher risk
patients. Age ,45 years, .25% of nodes positive, medial tumour
location and estrogen receptor (ER) negative (ER–ve) status have
been found to be statistically signiﬁcant independent factors associated
with greater local recurrence, meriting consideration and discussion of
post-mastectomy RT (Truong et al., 2005).
Adjuvant systemic therapy
Systemic adjuvant therapy includes all forms of endocrine therapy
(sometimes called hormone therapy (HT)) and/or cytotoxic therapy
used in conjunction with local surgical treatment for early breast
cancer. The aim of adjuvant systemic therapy is to eradicate microme-
tastases. There is Level 1 evidence to demonstrate a signiﬁcant beneﬁt
from adjuvant chemotherapy and endocrine therapy both in terms of
relapse-free survival and overall survival. In younger women (,50
years), six cycles of an anthracycline-based combination chemotherapy
(e.g. with FEC [5-ﬂuorouracil/epirubicin/cyclophosphamide] or FAC
[5-ﬂuorouracil/doxorubicin/cyclophosphamide]) are associated with
a proportional reduction in mortality of 38% which approximates
to a 5–15% absolute improvement in survival at 15 years of follow-up,
depending on the underlying risk of recurrence (Early Breast Cancer
Trialists’ Collaborative Group, 2005; Early Breast Cancer Trialists’
Collaborative Group et al., 2008). This may now be even higher
with more current chemotherapy regimens (such as ‘dose dense che-
motherapy’ where chemotherapy is administered every 2 weeks
rather than 3 weeks with white cell growth factor support) and the
addition of taxanes (De Laurentiis et al., 2008). The absolute beneﬁt
of chemotherapy is also related to patient age and receptor status
as well as a number of other pathological factors. Human epidermal
growth factor receptor-2 (HER2) testing is now routine, and there is
very good evidence from RCT to demonstrate a signiﬁcant improve-
ment in relapse-free survival and overall survival with adjuvant trastu-
zumab in women with HER2 positive breast cancer (as reviewed by
Baselga et al. (2006)). The details of all the chemotherapy regimens
and current trials are beyond the scope of this review, but the
drugs used and the doses as well as the number of cycles can increase
the likelihood of amenorrhoea and infertility.
For pre-menopausal women with hormone receptor positive
(HRþve) tumours, 5 years of tamoxifen will reduce the annual
breast cancer death rate by 31%, independent of the use of che-
motherapy or age. HRþve indicates ER and/or progesterone recep-
tor (PR) positive. Fifteen years after initial therapy, these beneﬁts
translate into average absolute reductions in recurrence of 11.8%
(SE 1.3) and in breast cancer mortality of 9.2% (SE 1.2) which approxi-
mates a 4–12% absolute gain depending on the underlying risk.
Meta-analysis of multiple randomized trials conﬁrms that combining
anthracycline-based chemotherapy with 5 years of tamoxifen, in
women with HRþve disease, reduces the risk of dying from breast
cancer by 57% (Early Breast Cancer Trialists’ Collaborative
Group, 2005). For example, if the risk of dying over the next 15
years is 25% without adjuvant therapy, this may be reduced to
12%. The greater the risk of relapse, the greater the potential of
beneﬁt from adjuvant treatment.
Current areas of controversy include the existence of any additional
beneﬁt of ovarian suppression by gonadotrophin-releasing hormone
(GnRH) analogues as endocrine therapy for young women with ER
positive early breast cancer, particularly in those who retain ovarian
function after chemotherapy and who are on tamoxifen (Bao and
Davidson, 2007). The frequency of use of GnRH analogues in commu-
nity practice is unknown, and their role is being addressed in the multi-
national intergroup Suppression of Ovarian Function Trial (SOFT).
Similarly, ongoing RCTs are addressing the role of hormonal therapy
alone with either ovarian suppression and tamoxifen, or tamoxifen
alone instead of chemotherapy in selected young women with ER
positive early breast cancer. In a recently reported study in pre-
menopausal women with HRþve disease, adjuvant oophorectomy
plus tamoxifen compared with observation alone lead to a signiﬁcantly
improved disease-free survival rate at 5 years (83 versus 61%) and 10
years (66 versus 47%) (Love et al., 2008).
Extensive evidence derived from RCT’s of systemic adjuvant therapy
in early breast cancer has lead to the development of decision-making
tools, such as adjuvant online (http://www.adjuvantonline.com), which
help health professionals make individualized estimates of the risk of
cancer-related mortality or relapse without systemic adjuvant therapy
and estimates of the reduction of these risks with therapy based on
patient age, tumour size, nodal involvement, histological grade, etc.
(Ravdin et al., 2001). These estimates are then provided on printed
sheets in simple graphical and text formats that can be used in consul-
tations and allow individual women to be informed and involved in their
treatment decisions. The accuracy of these estimates of treatment
beneﬁt in the very young is uncertain as relatively few would have par-
ticipated in the large randomized trials that contributed to the evidence.
Prognosis in younger women
The majority of breast cancers presenting in young women are inva-
sive cancers and most are inﬁltrating ductal cancers. Younger
women are more likely to present with larger tumours and appear
to have worse outcomes stage for stage in some but not in all
studies (Aebi et al., 2000; Maggard et al., 2003; El Saghir et al.,
2006). This apparent difference in prognosis may relate to differences
in the biology of breast cancer in younger women (Anders et al.,
Breast cancer and reproduction 3252008). The most important prognostic factors include tumour size and
nodal status as well as histological grade and HER2 and HR status.
Younger women are more likely to have higher grade, HR–ve
tumours with a high proliferative fraction and lymph vascular invasion.
Colleoni et al. (2002) reported that young women ,35 years were
more likely to have ER2ve (38.8 versus 21.6%, P , 0.001), PR2ve
(49.1 versus 35.3%, P ¼ 0.001) tumours compared with older
pre-menopausal women. The impact of HR status on prognosis in
younger women is controversial, but a large population study from
Denmark has recently found that a positive HR status does not
confer a negative impact on survival in young women as has been pre-
viously reported (Bentzon et al., 2008). It is now well accepted that
breast cancer is a heterogeneous disease encompassing several dis-
tinct entities with different morphological and immunohistochemical
features and varying biological behaviour and prognosis. For
example, it is now recognized that ‘triple negative’ (ER–ve, PR–ve
and HER2–ve) and basal-like breast cancers are more common in
younger women and have an aggressive clinical behaviour and are
more likely to relapse within the ﬁrst 5 years (Rakha et al., 2008).
An understanding of all these prognostic factors and an appreciation
of the difﬁculty of accurately predicting prognosis in an individual are of
particular importance when counselling the patient about fertility
interventions (see below). Close communication with the treating
oncologists should provide the fertility team with a better appreciation
of the likely prognosis, and this should be factored into decision-
making. This ideally should have been discussed in detail with the
patient prior to referral for fertility intervention. Novel tools for pre-
dicting recurrence using gene arrays such as oncotype DXTM and
MammaPrint
w are being used and their role under investigation
(reviewed by Ross et al. (2008)). An important question apart from
overall prognosis that often is raised is when the patient is at most
risk of relapse and how long this risk persists? There are data to
suggest that the hazard of recurrence is greatest (i.e. 13%) between
years 1 and 2 after surgery and then it falls consistently over time.
After 5 years, the recurrence risk averages around 4% per year in
the study reported by Saphner et al. (1996). Patients with HR–ve
tumours had a higher recurrence risk in years 0–5, whereas the
hazard of recurrence for women with HRþve cancers was relatively
constant in the ﬁrst 5 years after diagnosis and from years 5 to12, high-
lighting the very different natural history between HRþve and HR–ve
tumours and raising the question as to what the optimal duration of
hormonal therapy should be in women with HRþve breast cancers,
as shown in Fig. 1 (Saphner et al., 1996). It should also be pointed
out that these data on the annual risks of recurrence were derived
from seven adjuvant studies carried out over 20 years ago and
included both pre-menopausal and post-menopausal women with
node negative and node positive breast cancers. Furthermore, the
adjuvant treatments used would not be considered standard of care
today and the study also included controls who did not receive adju-
vant systemic therapy, suggesting that the annual hazard of recurrence
is likely to lower than presented in Fig. 1. Pre-menopausal patients had
a lower annual risk of recurrence than post-menopausal patients in this
study. More recently, Demicheli et al. (2004) reported the results of a
study of the hazard rate for recurrence in the ﬁrst 4 years after mas-
tectomy alone in more than 1000 patients. They found a sharp two-
peaked hazard function for node positive pre-menopausal patients
with a steep peak at 8–10 months after mastectomy and a broader
second peak that reached its maximum at 28–30 months. These
data may help women decide on the timing of pregnancy after diagnosis.
Breast cancer susceptibility
gene carriers
Hereditary breast cancer accounts for 5–10% of all breast carcinomas
and most are attributed to autosomal dominant germline mutations in
breast cancer susceptibility gene 1 (BRCA1) and breast cancer suscep-
tibility gene 2 (BRCA2) (Malone et al., 2000). The likelihood of a
BRCA mutation is higher in women with breast cancer under the
age of 45 with a strong family history of breast and/or ovarian
cancer. Although there is some variability between different series,
there are population-based studies that have demonstrated BRCA1
and BRCA2 mutations in 9% of women under 40 (Loman et al.,
2001). In the study of Loman et al., the subset of women with a
strong family history of breast or breast/ovarian cancer had almost
a 40% risk of carrying a BRCA1 or BRCA2 mutation. There are also
a number of other less common breast cancer susceptibility genes
and syndromes that are beyond the scope of this review. Women
with BRCA gene mutations tend to develop breast cancer at a
younger age and are at greater risk of bilateral breast cancer at pres-
entation as well as increased risk of subsequently developing a contral-
ateral breast cancer (Ford et al., 1994). BRCA1 mutation carriers have
a 50–80% lifetime risk of breast cancer and a 40–60% risk of ovarian
cancer, with the median age at diagnosis in the mid-40s. The breast
cancer risk is similar in BRCA2 mutation carriers, but the lifetime
risk of ovarian cancer is 15% and tends to occur in post-menopausal
women in their 60s. For BRCA mutation carriers diagnosed with
breast cancer, the risk of a recurrence or a new primary in the ipsilat-
eral breast in women who have breast conserving surgery is estimated
to be as high as 20–50% at 10 years, and the lifetime risk for a con-
tralateral second primary cancer is 40–60% in women diagnosed
with breast cancer under 40 years (Chen et al., 1999; Weitzel et al.,
2003).
Figure 1 Annual hazard of recurrence of 3563 patients separated
by ER status. ER, estrogen receptor.
Reproduced from Saphner et al. (1996) with permission. The mean
follow-up times for ERþve and ER–ve patients were 8.1 and 8.0
years, respectively.
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with worse prognostic features, and outcome may be improved by adju-
vantchemotherapy.Hence,evensmallnodenegativetumoursinBRCA1
carriers are offered adjuvant chemotherapy. Breast cancers in BRCA2
carriers are more similar to sporadic tumours. The optimal chemother-
apy for BRCA-related breast cancers is being actively investigated and is
beyond the scope of this review (Quinn et al., 2007; Rottenberg et al.,
2007). Newer targeted therapies such as poly (ADP-ribose) polymerase
inhibitors which selectively target BRCA-related breast and ovarian
cancers and spare normal heterozygous cells are being investigated in
clinical trials (www.clinicaltrials.gov).
The management of women with BRCA mutations is complex,
requires a multi-disciplinary team approach and includes counselling
about cancer risk, surveillance options and discussion of risk-reducing
surgery including prophylactic mastectomy and/or oophorectomy.
Prophylactic mastectomy is very effective and reduces the risk of
breast cancer by over 90% (Hartmann et al., 2001; Rebbeck et al.,
2004).
Prophylactic bilateral salpingo-ophorectomy (BSO) signiﬁcantly
reduces the risk of both ovarian and breast cancer in BRCA1/2 car-
riers (Bermejo-Perez et al., 2007) BSO reduces the risk of ovarian
cancers by 85–90% and reduces the risk of breast cancer by 50%
(Kauff and Barakat, 2007). The reduction in the risk of breast cancer
even in women with BRCA1-associated breast cancer which is com-
monly ER2ve may seem counterintuitive, but there is growing evi-
dence to suggest that many ER2ve breast cancers evolve from
ERþve precursors (Allred, 2004). Risk reduction following BSO may
differ for BRCA1/2 carriers. Case–control studies suggest that pro-
phylactic oophorectomy may result in a greater reduction in breast
cancer risk in BRCA1 carriers who undergo surgery before 40 years
of age, compared with BRCA2 carriers (Eisen et al., 2005). Both
ovaries and fallopian tubes should be removed since both are at
increased risk for malignant transformation (Levine et al., 2003).
Indeed, there is growing evidence to suggest that most BRCA-related
‘ovarian cancers’ actually arise in the ﬁmbrial end of the fallopian tube
which probably explains why transvaginal ultrasound screening for
ovarian cancer does not appear to be an effective screening modality
(Callahan et al., 2007). Hysterectomy at the time of BSO is controver-
sial, and the additional morbidity needs to be taken into account and
weighed against the potential risks of combined HT for the manage-
ment of menopausal symptoms and bone protection.
Effects of breast cancer
treatment on reproductive
function
Around 2.7% of breast cancers occur in women of peak reproductive
age (25–35 years) (Axelrod et al., 2008). The growing tendency in
developed countries for delayed childbearing may increase breast
cancer risk and also increases the number of women who have not
yet started or completed their families when breast cancer is diag-
nosed. In addition to possibly having an inferior outcome compared
with older women as discussed above (Chen et al., 2003; Maggard
et al., 2003; Rapiti et al., 2005; El Saghir et al., 2006), young breast
cancer patients may face dilemmas regarding fertility, pregnancy and
contraception (Partridge et al., 2004) and report having difﬁculty
obtaining information in these areas (Thewes et al., 2005).
Breast cancer is likely to have a negative impact on reproductive
function for a number of reasons. First, from the toxic effect of che-
motherapy on ovarian follicles, secondly from the advice commonly
given to patients to delay pregnancy for at least 2 years following a
diagnosis of breast cancer and thirdly because endocrine therapy com-
monly continues for at least 5 years, after which fertility is likely to be
reduced due to age-related decline. In addition, ovarian ablation or
bilateral oophorectomy may be advised for some younger women
with HRþve cancers (Early Breast Cancer Trialists’ Collaborative
Group, 2005; Bao and Davidson, 2007) or as risk-reducing surgery
in BRCA1/2 gene mutation carriers as discussed earlier.
Ovarian function following chemotherapy
for breast cancer
Ovarian dysfunction following chemotherapy for breast cancer is
related to patient age, to ovarian function at the time of treatment
and to the speciﬁc agents used, particularly the dose of alkylating
agents such as cyclophosphamide (Lee et al., 2006). Common
effects of chemotherapy on ovarian function include temporary ame-
norrhoea due to loss of the developing cohort of ovarian follicles or
permanent amenorrhoea due to loss of remaining follicles (Oktay
et al., 2006a, b). Chemotherapy causes depletion of the primordial fol-
licle pool in a drug- and dose-dependent manner (Sonmezer and
Oktay, 2004). Prevalence rates of temporary and permanent amenor-
rhoea vary due to differences in treatment regimens, patient charac-
teristics and outcome measures used. For those who do resume
normal menstrual cycles, ovarian damage due to chemotherapy can
still be identiﬁed. There is marked follicular depletion (Oktem and
Oktay, 2007), fertility is impaired and the mean age at menopause
is reduced (Partridge et al., 2007).
Amenorrhoea rates following combination chemotherapy consisting
of cyclophosphamide þ methotrexate þ 5-ﬂurouracil (CMF regimen)
range from 21 to 71% in women aged  40 years, and from 40–
100% in older women (Gadducci et al., 2007), although this combi-
nation is now rarely used. In most series, anthracycline-based adjuvant
chemotherapy regimens appear to have a lower incidence of amenor-
rhoea, which is probably due to the lower cumulative cyclophospha-
mide dose administered compared with that given in the CMF
regimen.
The impact of taxanes on the incidence of amenorrhoea is uncer-
tain with conﬂicting results. Some studies suggest no additional
effect (Tham et al., 2007), whereas others report that the rates of
amenorrhoea may be increased (Martin et al., 2005; Swain et al.,
2005; Petrek et al., 2006). There may also be a difference between
docetaxel and paclitaxel (Alton et al., 2004), but there is insufﬁcient
data to comment on the impact of different schedules of paclitaxel
(e.g. weekly, dose dense or three-weekly dosing) on the rate of
amenorrhoea.
As might be expected, younger breast cancer patients are less likely
to experience amenorrhoea or menstrual cycle changes following che-
motherapy. A recent retrospective review of 160 patients aged from
18 to 34 years (median age 32 years) treated with alkylating agent-
based chemotherapy regimens (CMF) and 80 with anthracycline-based
regimens (AD) and a median follow-up period of 54 months reported
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59 (36.9%) patients, 25 (31.3%) of those treated with CMF and 34
(42.5%) with AD. Amenorrhoea occurred after a median two cycles
of chemotherapy (range: 1–6 cycles). Menstruation resumed in 49
(83.1%) patients, 20 (80%) of those treated with CMF and 29
(85.3%) with AD. The median time to resumption of menstruation
was 3.5 months (Kil et al., 2006).
As a rule of thumb, chemotherapy for breast cancer appears to add
about 10 years to ovarian age in terms of reproductive function.
Unfortunately, many young women are not fully aware or well
informed of the potential adverse reproductive effects of chemother-
apy on fertility or fail to understand the possible consequences of
treatment while making treatment decisions shortly after the diagnosis
of breast cancer (Duffy et al., 2005).
Endocrine therapy and reproductive function
Around 60% of pre-menopausal breast cancer patients will have
HRþve cancers and will be given endocrine therapy either alone (in
selectedpatients)ormorecommonlychemotherapyfollowedbyendo-
crinetherapy.Endocrinetherapyregimensvaryaccordingtopatientand
tumour characteristics, but may include tamoxifen or ovarian suppres-
sion or ablation or both. Aromatase inhibitors (AIs) are currently only
used in post-menopausal women, and their role in conjunction with
GnRH agonists in younger women is under investigation.
Tamoxifen
Tamoxifen is a mixed estrogen agonist and antagonist which com-
monly induces hot ﬂushes, night sweats, vaginal discharge, itching or
dryness (Mourits et al., 2001). Tamoxifen is often reported to cause
menstrual disorders but evidence for this is lacking. Tamoxifen may
also stimulate ovulation (Oktay et al., 2005) and is licensed in the
UK for the treatment of anovulatory infertility. It is important that
younger women realize that tamoxifen is not a contraceptive and
carries a risk of stimulating multiple ovulations and hence multiple
pregnancy. In post-menopausal women, tamoxifen increases the risk
of endometrial polyps, hyperplasia and a 2-fold increased risk of endo-
metrial cancer (van Leeuwen et al., 1994), but this is far less likely in
pre-menopausal women.
Tamoxifen has a similar chemical structure to diethylstilbestrol.
Concern that tamoxifen may be teratogenic arose from animal studies
showing increased genital tract malformations (Barthelmes and Gately,
2004). However, there relatively little human evidence that tamoxifen
isteratogenic. There have been four reports of craniofacial abnormalities
associated with tamoxifen use in the ﬁrst trimester (Cullins et al., 1994).
A further case report linked tamoxifen with genital tract abnormalities
in humans (Tewari et al., 1997). No fetal abnormalities were seen in
theoffspringof85womenwhobecamepregnantwhiletakingprophylac-
tictamoxifenforthepreventionofbreastcancer(Clark,1993).However,
there are no long-term data from children exposed to tamoxifen during
development. This is important because the effects of diethylstilbestrol
only became evident in later life.
Assessment of fertility following breast
cancer treatment
Lack of prospective studies with current chemotherapeutic regimens
makes it difﬁcult to predict their impact on future fertility. Most
studies have used amenorrhoea or menstrual irregularity as an end-
point, but these do not reliably relate to fertility. Recent studies
have assessed the impact of chemotherapy on ovarian function using
composite measures derived from assisted reproductive technology
(ART) studies. Ovarian reserve testing (ORT) includes timed (Day
2–5 of the menstrual cycle) follicle-stimulating hormone (FSH) and
lutenizing hormone, estradiol, inhibin B and anti-Mullerian hormone
(AMH) in combination with ovarian antral follicle count determined
at transvaginal ultrasound. Declining ovarian reserve is reﬂected in
lower circulating levels of estradiol, inhibin B and AMH produced by
the granulosa cells of the ovarian follicle and reduced numbers of
antral follicles. These tests appear to predict the outcome in ART
(Bukulmez and Arici, 2004), and control levels have been published
in a healthy and subfertile populations (Broekmans et al., 2006).
ORT has not been shown to reliably predict pregnancy, but appears
to predict earlier age at menopause (Lutchman Singh et al., 2005).
The validity of ORT following chemotherapy for breast cancer is not
yet established, and this battery of tests is not commonly available
in clinical practice. ORT following chemotherapy suggests that it
does not reliably predict the response to ovarian stimulation (Lutch-
man Singh et al., 2005). Prospective studies in breast cancer patients
indicate that ovarian reserve declines during chemotherapy, with regi-
mens containing taxanes in addition to cyclophosphamide showing
increased gonadotoxicity. Gonadotrophin suppression with endocrine
therapy resulted in expected falls in estradiol (P , 0.05) and inhibin B
(P , 0.001) levels, but also resulted in a delayed fall in AMH level after
6 months (P , 0.0001). A fall in AMH may precede other changes in
ORT following breast cancer chemotherapy (Anderson et al., 2006).
Preservation of fertility in breast
cancer patients
Breast cancer patients who have not started or completed their
families may wish to consider available options to try and increase
the chances of successful pregnancy following chemotherapy. Cur-
rently, there are no treatments which are guaranteed to preserve fer-
tility. For women with breast cancer, the issue of fertility preservation
is more complex than in other cancers with concerns that fertility
preservation strategies and/or subsequent pregnancy may increase
the risk of cancer recurrence, particularly in women with
hormone-receptor positive disease (Partridge et al., 2007). The poten-
tial risks and beneﬁts of treatment should be considered on an individ-
ual basis (Table II). In evaluating patient options, a critical factor is
whether the patient has a fertile male partner with whom she is plan-
ning a family. For single women, the options are currently very limited.
Fertility preservation options can be divided into those which aim to
reduce the impact of chemotherapy on ovarian function, those which
aim to remove and preserve ovarian tissue before starting chemother-
apy and those which aim to produce mature oocytes or fertilized
embryos for future use. Sonmezer and Oktay (2006) have proposed
an algorithm to aid decisions regarding fertility preservation based
on cancer treatment choices and age that may be a useful tool in clini-
cal practice (Fig. 2).
Multiple small observational studies have demonstrated a protective
effect on ovarian function when GnRH agonists are given concurrently
with chemotherapy (Blumenfeld, 2007). A recent small RCT
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GnRH agonist before chemotherapy resumed spontaneous menses
and ovulation (Badawy et al., 2008) and this requires conﬁrmation.
The mechanisms of action of GnRH agonists in preserving ovarian
function are not fully understood, but may include interruption of
FSH secretion, decrease in utero-ovarian perfusion, activation of
GnRH receptors, up-regulation of intra-gonadal antiapoptotic mol-
ecules such as sphingosine-1-phosphate or by protection of undiffer-
entiated germ line stem cells (Blumenfeld, 2007).
Embryo cryopreservation is a standard, widely available treatment
for infertility that may be used in breast cancer patients who have a
male partner or who have access to donor sperm. Although success
rates with frozen embryos are somewhat reduced, these women
can undergo ovarian stimulation, oocyte harvesting followed by IVF
and embryo freezing for attempted pregnancy when breast cancer
treatment is completed. Advantages of this strategy are the relatively
high success rates. Disadvantages include the need for ovarian stimu-
lation (and subsequent high estradiol levels), cost (variable), possible
delays in commencing adjuvant treatment (Lee et al., 2006) and the
risk of cancelled cycles. Strategies to avoid high estrogen levels
include ‘natural cycle’ IVF, albeit with very low pregnancy rates
(Oktay, 2005). Ovarian stimulation protocols using the AI letrozole,
together with gonadotrophin treatment (FSH), resulted in signiﬁcantly
lower peak estradiol levels than tamoxifen alone or plus FSH, and 44%
reduction in the amount of gonadotrophin needed but similar length of
stimulation and number of embryos obtained. Fertilization rates were
similar to conventional ovarian stimulation protocols and 81% com-
pleted their IVF cycles within 8 weeks of surgery (Oktay et al.,
2006a, b). Short-term follow-up (around 1 year) is reassuring that
this intervention does not appear to affect breast cancer prognosis
(Azim et al., 2008), but long-term data are not yet available. In patients
with potentially fatal disease, the issue of what to do with the embryos
if the patient dies prior to their use should be addressed.
For those who do not have a male partner, oocyte cryopreservation
may be considered. However, success rates with this method are
three to four times lower than that seen with embryo cryopreserva-
tion, at 20% at best (Partridge et al., 2007). Like embryo cryopreser-
vation, this approach may incur expense, treatment delay and requires
ovarian stimulation. Ovarian tissue cryopreservation for future ortho-
topic or heterotopic reimplantation and stimulation has limited inter-
national experience and relatively few successful pregnancies (Oktay
and Tilly, 2004). Survival of transplanted ovarian follicles appears to
be reduced in older women (Partridge et al., 2007). It remains
unclear whether removing ovarian tissue for this highly experimental
technique augments or reduces fertility in younger women with
breast cancer. Further, it is possible that reimplanted ovarian tissue
may harbour breast cancer micrometastases that may increase recur-
rence risk, although this is more a theoretical risk and there are no
supportive clinical data. Women who carry a pathogenic BRCA1 or
2 gene mutation have a 50% risk of transmitting this mutation to
their offspring. Recent advances in pre-implantation genetic diagnosis
have allowed the selection of unaffected embryos during IVF protocols
in these women (Jasper et al., 2008).
Ovum donation is another option and has the beneﬁt of using fresh
ova from a donor (with higher success rates than frozen ova). This
may be particularly appealing to women who do not, at the time of
.............................................................................................................................................................................................
Table II Advantages and disadvantages of fertility-preserving strategies
Option Advantage Disadvantage
Potential fertility preserving strategies
1. IVF and embryo cryopreservation Relatively effective in achieving pregnancy Requires a male partner and embryos legally owned by both
partners
Clinically available Likely to increase circulating estrogen levels which may impact on
prognosis of ER positive breast cancer
May delay chemotherapy
In gene mutation, carriers may transmit increased cancer risk to
offspring
2. Ovarian stimulation and oocyte
cryopreservation
Does not require a male partner Very few successful pregnancies
Likely to increase circulating estrogen levels which may impact on
prognosis of ER positive breast cancer
May delay chemotherapy
In gene mutation, carriers may transmit increased cancer risk to
offspring
3. Ovarian tissue cryopreservation and
xenotransplantation
Does not require a male partner Very few successful pregnancies
Does not require ovarian stimulation and
increased estradiol levels
May reimplant ovarian tissue affected by micrometastases
Unlikely to delay chemotherapy In gene mutation, carriers may transmit increased cancer risk to
offspring
Surgical procedure
4. Ovarian suppression with GnRH
agonists
Does not require a male partner Efﬁcacy in fertility preservation not conﬁrmed
Simple to administer Side effects unknown
Unlikely to delay chemotherapy
Relatively less invasive
ER, estrogen receptor; GnRH, luteinizing hormone releasing hormone; IVF, in vitro fertilization.
Breast cancer and reproduction 329diagnosis, have a partner with whom they are considering having a
child. For BRCA1 or 2 mutation carriers, there is a potential beneﬁt
that the child will not inherit their gene mutation. There is no required
delay in cancer treatment as this process would occur after cancer
treatment is completed, however, similar to IVF, the recipient of the
ova may require hormonal stimulation (to prepare the endometrium
for embryo transfer) and subsequent increased estradiol levels. The
recipient will incur not only the cost for her own stimulation and trans-
fer but also the costs for the ovarian stimulation and collection of the
ova from the donor and other medical costs including counselling.
Also, the patient will usually need to ﬁnd the oocyte donor herself.
Contraception following
breast cancer
Pregnancy should be avoided during active treatment of breast cancer,
so adequate, acceptable and effective contraception is a priority. Hor-
monal contraceptives remain contraindicated, although the evidence
for harm is difﬁcult to establish. This is particularly relevant given
the current availability of low-dose long-acting progestogen only con-
traceptive such as the levonorgestrel-releasing intra-uterine system
(Mirena) which delivers high local but low systemic doses of progesto-
gen and offer highly effective contraception. Mirena has been used fol-
lowing breast cancer, and may reduce the risk of endometrial
pathology in tamoxifen users (Chan et al., 2007), but studies are gen-
erally small and have not included recurrence or new cancers as an
endpoint. Subgroup analysis of a recent retrospective cohort study
reported a trend towards increased breast cancer recurrence rate in
women using Mirena at the time of diagnosis who continued with
the device in situ. This was not seen in those who had Mirena inserted
after a breast cancer diagnosis (Trinh et al., 2008). This highlights the
need for prospective studies to address the safety of Mirena after
breast cancer. Meanwhile, patients should be advised that the safety
of Mirena on breast cancer recurrence is unknown and alternative
non-hormonal contraception is recommended.
Observational studies in BRCA1 and 2 unaffected mutation carriers
have demonstrated that the oral contraceptive pill reduces the risk of
ovarian cancer (McLaughlin et al., 2007), but may be associated with
an increased risk of breast cancer, although the data regarding this
are conﬂicting (Brohet et al., 2007). Reassuringly, Lee et al. recently
reported the results of a population-based study that found no associ-
ation between oral contraceptive use and breast cancer risk in
BRCA1/2 mutation carriers. Further conﬁrmation that currently avail-
able low-dose oral contraceptives do not increase breast cancer risk in
carriers is important from a public health perspective, given the high
prevalence of oral contraceptive use. There is still a paucity of
evidence-based information on oral contraception and risk of breast
cancer in BRCA1 and 2 carriers to make deﬁnitive recommendations.
Pregnancy following breast
cancer
Less than 10% of women previously diagnosed with breast cancer sub-
sequently become pregnant (Danforth, 1991; Kroman et al., 1997).
Figure 2 A proposed algorhythmic approach to decision-making for fertility preservation in breast cancer patients.
Reproduced from Sonmezer and Oktay (2006) with permission. Embryo cryopreservation using letrozole is a novel stimulation protocol in
breast cancer patients, and long-term follow-up data are awaited. Ovarian tissue and oocyte cryopreservation are experimental technologies.
cryo, cryopreservation; FP, fertility preservation; TMX, tamoxifen
330 Hickey et al.This is around half the pregnancy rate seen in an age-matched group
who have not had breast cancer (Ives et al., 2007). Of these pregnan-
cies, between 14 and 44% are terminated (Barthelmes and Gately,
2004). Relatively few studies have addressed the impact of pregnancy
following breast cancer (Ives et al., 2007). Further, those who become
pregnant following breast cancer may be a self-selected group when
may not be representative of the larger population. Women carrying
hereditary gene mutations that increase the risk of cancer in their off-
spring may be particularly reluctant to have children (Smith et al.,
2004).
The use of adjuvant chemotherapy does not appear to affect the
outcome of pregnancy in women who become pregnant at least 6
months after diagnosis, with more women having a successful live
birth than having an abortion or miscarrying (Clark and Chua, 1989;
Reichman et al., 1994; Ives et al., 2007). Moreover, pregnancy does
not appear to adversely affect prognosis following a prior history of
breast cancer. The overall survival rates at 5 and 10 years were
found to be better for women who subsequently conceived in a
Western Australian population study (Ives et al., 2007) than has
been reported in similar cohorts (Velentgas et al., 1999; Blakely
et al., 2004). This apparent survival beneﬁt is probably due to a
‘healthy mother effect’ (Sankila et al., 1994), suggesting that breast
cancer survivors who subsequently conceive are a self-selecting
group of women with better prognosis. Retrospective case–
controlled studies report that subsequent live birth does not adversely
effect prognosis (Kroman et al., 1997; Barthelmes et al., 2005). The
little available information appears to show no increase in the inci-
dence of prematurity, stillbirth or congenital malformations in their
babies. Small series following these children are also reassuring
(Mintzer et al., 2002), but little is known about the long-term
impact of chemotherapy or endocrine therapy on offspring (Cardonick
and Iacobucci, 2004). The largest reported series included 84 children
who were exposed to a variety of chemotherapy agents in utero and
followed for a median of 18 years. Reassuringly, no adverse sequelae
were documented although the numbers are relatively small (Aviles
and Neri, 2001).
Women are commonly recommended to delay pregnancy for at
least 2 years following a diagnosis of breast cancer as most recur-
rences will develop in that time (Averette et al., 1999). The optimal
time to delay pregnancy following the diagnosis and treatment is
unknown and is an important issue for all patients considering preg-
nancy. The risk of relapse and the time to recurrence is related to
many factors including the stage, grade and nodal status as well as
the HR status. Saphner et al. (1996) have reported annual hazard
rates of recurrence after primary therapy. These results should be
interpreted with caution since chemotherapy regimens have now
changed and the number of younger women included is not stated.
For the entire group, the risk of recurrence was greatest (13.3%)
for the interval between years 1 and 2 after surgery. This risk then
decreased consistently, and beyond 5 years averaged about 4.3%
per annum in women with HRþve breast cancer in the Saphner
study (Fig. 1), but there are some caveats with these ﬁgures, as
discussed earlier. Patients with HR–ve tumours had a higher hazard
of recurrence in years 0–5 which then decreased over time,
whereas the hazard of recurrence for women with HRþve cancers
was relatively constant in the ﬁrst 5 years after diagnosis and from
years 5 to 12. This highlights the distinct natural history of HRþve
and HR–ve tumours. More recently, we have recognized that there
are a number of different sub-types of breast cancer, some of which
are more common in younger women and they appear to have a
higher risk of relapse in the ﬁrst 2–3 years after diagnosis. These
estimates of recurrence should be considered in decisions regarding
subsequent pregnancy. However, there is little evidence to show
beneﬁt to patients in waiting more than 2 years after diagnosis of
breast cancer to attempt pregnancy, as long as adjuvant therapy has
been completed. In addition, patients need to understand that there
is a risk that breast cancer may return and this may affect their
ability to care for future offspring. Over 50% (of 126) of breast
cancer patients in a population-based series in Western Australia con-
ceived within 2 years of diagnosis and this did not seem to adversely
affect their survival (Ives et al., 2007).
In women with BRCA1 or 2 gene mutations, the risks of pregnancy
are not well established. Observational studies suggest that BRCA1
mutation carriers who have their ﬁrst child at 30 years or older may
have a reduced personal risk of breast cancer (Andrieu et al., 2006).
However, the opposite effect has been observed in BRCA2 mutation
carriers where late ﬁrst pregnancies (over 30 years) are linked with
increased risk of breast cancer (Andrieu et al., 2006).
Breastfeeding after breast cancer
It is well established that breast milk is the best source of nutrients for
babies (Helewa et al., 2002) Following breast cancer treatment,
women may need advice about their ability and the safety of breast-
feeding. Observational data suggest that breastfeeding does not
impact on breast cancer prognosis and that infants breastfed by
mothers with a history of breast cancer or current cancer do not
have an elevated risk of cancer (American Academy of Pediatrics.
Work Group on Breastfeeding, 1997; Michels et al., 2001; Helewa
et al., 2002).
All younger women having breast conserving surgery will be advised
to also have RT and will then be unlikely to be able to feed from the
treated breast (Tralins, 1995; Moran et al., 2005). Women can suc-
cessfully breastfeed from the other breast after breast cancer if they
do not undergo pharmacological suppression of lactation (Higgins
and Haffty, 1994; Moran et al., 2005), and it is possible to breastfeed
exclusively from one breast (Sacchini et al., 2006).
Menopausal symptoms following
breast cancer treatment
Menopausal symptoms are a frequent and troublesome side effect of
breast cancer therapy in women of all ages. Hot ﬂashes, night sweats,
sexual dysfunction, poor sleep and tiredness are common (Saunders
et al., 2008). Vasomotor symptoms, particularly hot ﬂushes, appear
to be more severe than in women who have not had breast cancer
treatment (Couzi et al., 1995; Carpenter et al., 1998; Santoro,
2004). Vasomotor symptoms such as hot ﬂashes are the most
common side effect (Cella and Fallowﬁeld, 2008). Up to 20% of
breast cancer patients consider stopping or actually cease endocrine
therapy because of menopausal symptoms, primarily hot ﬂashes (Fel-
lowes et al., 2001; Barron et al., 2007), despite its established role in
reducing recurrence. Atrophic vaginitis affects many women using
endocrine therapy for breast cancer, particularly those using AIs
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vaginitis but also to changes in body image, libido and self-esteem
and may be more common in younger women (Canney and Hatton,
1994; Schover, 1994; Andersen et al., 2007).
The recommended duration of initial adjuvant endocrine therapy is
5 years and some patients may beneﬁt from a further 5 years of treat-
ment. With such long-term treatment duration, it is critical to address
morbidity associated with treatment side effects in an effort to opti-
mize adherence to therapy and quality of life.
Use of estrogen and progestin in breast
cancer patients
Estrogen-containing HT is the most effective and well-studied treat-
ment for menopausal vasomotor symptoms and atrophic vaginitis in
healthy post-menopausal women (MacLennan et al., 2004), but the
efﬁcacy and safety of HT following breast cancer is contentious.
There are two large RCTs investigating the use of HT after diagnosis
of early stage breast cancer having contradictory results. The Stock-
holm and HABITS trials were similar in design, though a goal of the
Stockholm protocol was to minimize the use of progestogen com-
bined with estrogen. The HABITS trial was stopped prematurely
because it identiﬁed a signiﬁcantly higher risk of recurrence in
women taking menopausal HT (relative hazard [RH] ¼ 3.3, 95% con-
ﬁdence interval [CI] ¼ 1.5–7.4 at a median follow-up of 2.1 years),
whereas at a median follow-up of 4.1 years the risk of recurrence
was not associated with HT in the Stockholm trial (RH ¼ 0.82, 95%
CI ¼ 0.35–1.9) (Holmberg et al., 2004; von Schoultz and Rutqvist,
2005). HT was not effective in controlling hot ﬂashes in tamoxifen
users in one retrospective study (Sestak et al., 2006). Long-term use
of combined HT has been associated with an increased risk of new
breast cancers in some studies (Rossouw et al., 2002). In breast
cancer survivors, one RCT reports a 2- to 3-fold increased risk of
new primary or recurrent breast cancers in HT users (Holmberg
et al., 2008). Further, HT may compromise the effects of endocrine
therapy aimed at blocking the effects of estrogen, or reduce its pro-
duction in ERþve disease. In addition, combined HT increases
breast density, which may compromise the ability of mammography
to detect early cancers (Chiarelli et al., 2006). Consequently, many
women wish to avoid HT following breast cancer (Biglia et al.,
2003). Progestins are also effective for menopausal hot ﬂashes follow-
ing breast cancer (Loprinzi et al., 1994; Barton et al., 2002; Bordeleau
et al., 2007), but their safety is not established and their effects may
depend on circulating levels of estradiol. Of concern is that the
addition of progestin to estrogen for HT appears to increase the
risk of a primary breast cancer (Anderson et al., 2004).
The recent trial of tibolone after breast cancer (LIBERATE) has con-
cluded that tibolone increases the risk of new breast cancers or recur-
rence (Peter Kenemans, personal communication).
Use of estrogen and progestin in BRCA1/2
mutation carriers
Risk-reducing BSO in pre-menopausal BRCA1/2 mutation carriers will
induce surgical menopause. There are surprisingly few published
studies on the consequences of surgical menopause, but the observa-
tional literature suggests that symptoms may be more severe and
prolonged following BSO compared with spontaneous menopause
(Bachmann, 1999). Estrogen-containing HT may be of limited efﬁcacy
in relieving menopausal symptoms in these younger women
(Madalinska et al., 2006). Further, the impact of HT on subsequent
breast or ovarian cancer risk in these women is poorly understood.
One retrospective study (Rebbeck et al., 2005) was reassuring that
the reduction in breast cancer risk associated with BSO is not modi-
ﬁed by short-term use of HT. In the absence of other data, a decision
model has been developed which allows individualized assessment of
the impact of prophylactic BSO, bilateral prophylactic mastectomy and
HT use on life expectancy in BRCA1/2 carriers at age 30, 35 and 40.
The overall impact of HT use ranged from a gain of 0.79 years to a loss
of 1.09 years dependent on the age of BSO and the duration of HT
use. This suggests that the use of HT in BRCA1/2 users should be
guided by patient symptoms and issues around quality of life, in the
absence of clearer information about relative risks (Gallagher, 2007;
Metcalfe et al., 2007).
Management of menopausal symptoms
following breast cancer
Non-hormonal treatments for hot ﬂushes following breast cancer have
been extensively reviewed (Hickey et al., 2008). Currently, there is no
evidence that complementary or natural therapies are consistently
effective or safe following breast cancer. Further, although behavioural
or lifestyle changes have shown promise, efﬁcacy data are lacking.
A number of pharmaceutical therapies have been tested and appear
moderately effective in reducing the number and severity of hot
ﬂushes in breast cancer patients. These non-hormonal therapies do
not appear to impact on other common menopausal symptoms,
although some may improve sleep when sleep disturbance is due to
night sweats.
For breast cancer patients with moderate-to-severe hot ﬂashes, it is
reasonable to consider either serotonin-norepinephrine reuptake
inhibitor (SNRI) or selective serotonin reuptake inhibitor (SSRI)
either venlafaxine or paroxetine as ﬁrst-line approach. There are
few head-to-head studies between preparations, but venlafaxine
(37.5 mg daily increasing to 75 mg daily after 1 week) or paroxetine
(10 mg daily increasing to 20 mg daily after 1 week if symptoms
persist) has been extensively studied and appears effective, at least
in the short-term and adequately tolerated. If venlafaxine is not effec-
tive, it is reasonable to consider trying paroxetine and vice versa. In
those who are taking tamoxifen, preparations which induce
CYP2D6 (e.g. paroxetine and ﬂuoxetine) should be avoided since
these may interfere with the breakdown of tamoxifen to its active
metabolite (Stearns et al., 2003). SSRI and SNRI are contraindicated
in women taking monoamine oxidase inhibitors and should be used
cautiously or potentially avoided in women with bipolar disorder/
manic depression, because of the risk of inducing mania. If there is
no response in 4 weeks, then the treatment is unlikely to be effective.
Gabapentin (300 mg tds) appears be an effective alternative and
may be used as an alternative ﬁrst-line treatment, instead of SSRI/
SNRIs or where these are unsuitable (Pandya et al., 2005). There
does not appear to be a beneﬁt of adding gabapentin to SSRI/SNRI
(Loprinzi et al., 2007). Gabapentin may also be considered if sexual
dysfunction is a problem prior to SSRI/SNRIs or develops on this
therapy. For those with milder symptoms requesting treatment, cloni-
dine (25 mg bd) or vitamin E (800 IU/day) shows moderate efﬁcacy
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pausal symptoms in both pre and post-menopausal women. Changing
or stopping endocrine therapy may be considered, but should be
managed in consultation with the oncologists, preferably within a
multi-disciplinary treatment approach (Hickey et al., 2008).
Atrophic vaginitis following breast cancer
Symptomatic atrophic vaginitis affects around one-third of post-
menopausal women after breast cancer (Leining et al., 2006) and is
particularly troublesome in those using AIs (Fallowﬁeld et al., 2004).
Increasing use of AIs in post-menopausal breast cancer patients
means that the number of women complaining of symptomatic
atrophic vaginitis following breast cancer treatment is likely to increase
(Cella et al., 2006).
Vaginal estrogens are an effective treatment for vaginal dryness
(Suckling et al., 2007) and are more effective than non-hormonal
vaginal lubricants such as Replens
w in women who have not had
breast cancer (Nachtigall, 1994). Although systemic estrogens are
avoided following estrogen-receptor positive breast cancer, vaginal
estrogens are commonly used via an estradiol-releasing vaginal ring,
estrogen-based vaginal creams, pessaries containing estriol and a slow-
release 17b estradiol tablet. However, there are few data on either
safety or efﬁcacy (Ponzone et al., 2005). Small retrospective studies
in breast cancer patients suggest that vaginal estrogens do not
adversely affect the outcome (Dew et al., 2003). Similarly, vaginal
estrogens were permitted in the placebo-controlled MA.17 trial of
letrozole as extended adjuvant therapy following 5 years of tamoxifen
without seeming to interfere with the observed efﬁcacy (Goss et al.,
2003). Although systemic absorption of vaginal estrogens is not sufﬁ-
cient to cause endometrial hyperplasia, it may be sufﬁcient to increase
circulating estradiol in breast cancer patients taking AIs (Kendall et al.,
2006). More information is needed about the safety of vaginal estrogens
following breast cancer. An alternative option is to use the less potent
estrogen, estriol which cannot be converted to estradiol. Vaginal prep-
arations containing estriol are as effective as those containing estradiol in
treating symptomatic women (Barentsen et al., 1997).
Sexual dysfunction following breast cancer
Both the diagnosis and treatment of breast cancer may impact nega-
tively on sexual function in women (Burwell et al., 2006). These are
likely to vary according to age, menopausal status and relationship
factors as well as the nature of surgical and endocrine treatments
(Cella and Fallowﬁeld, 2008). Sexual dysfunction is common in
women with atrophic vaginitis (Levine et al.) and may also relate to
changes in body image, libido and self-esteem after breast cancer
(Canney and Hatton, 1994). There are relatively few safe and effective
treatment options for hypoactive sexual desire disorder (HSDD). Sen-
sitive but direct questioning about sexual function may be needed
since patients may be reluctant to raise these issues themselves.
Vaginal dryness should be excluded as a contributory factor (Loprinzi
et al., 1997). Concurrent treatment with SSRI/SNRIs may cause/com-
plicate sexual dysfunction by reducing libido and causing anorgasmia.
Testosterone therapy is offered by some clinicians for HSDD, but
its safety and efﬁcacy have not been well established in healthy
women (Wierman et al., 2006) or after breast cancer (Barton et al.,
2007). There is some evidence that sexual problems after breast
cancer tend to decrease over time (Burwell et al., 2006). Type 5 phos-
phodiesterase inhibitors such as sildenaﬁl have been extensively
studies for female sexual dysfunction, but RCT have not shown signiﬁ-
cant beneﬁt (Basson et al., 2002). Small studies suggest that the anti-
depressant bupropion may improve sexual function in breast cancer
survivors (Mathias et al., 2006), but larger trials are needed to
conﬁrm this. Sex therapy may be helpful.
Treatment of bone loss
Abrupt withdrawal of circulating estrogen, such as occurs with
chemotherapy-induced ovarian failure, oophorectomy, GnRH agonist
therapy or with AIs, is accompanied by rapid bone loss (Sverrisdottir
et al., 2004). Chemotherapy per se has not been associated with bone
loss if it is not followed by ovarian failure (Shapiro et al., 2001).
Women who develop breast cancer may have a higher bone density
than those who do not, presumably secondary to effects of lifetime
exposure to circulating estrogen which has been linked to increased
riskofbreastcancer(Nguyenetal.,2000;Heshmatietal.,2002).Never-
theless,bonelossandincreasingriskoffractureisariskforbreastcancer
survivors (Chen et al., 2003). Tamoxifen preserves bone density and
reduces fractures in post-menopausal women by its estrogenic action
on bone (Love et al., 1992). Conversely, in pre-menopausal women
with endogenous circulating estrogen, tamoxifen is associated with
bone loss, presumably because of competitive binding to the ER
(Powlesetal.,1996).AIsarenowcommonlyusedasﬁrst-lineendocrine
therapy in HRþve post-menopausal women. However, bone loss with
the AIs is substantial and greatest for women within 4 years of meno-
pause and for women ,65 years of age. Fractures are signiﬁcantly
increased following AI use compared with tamoxifen (Coleman et al.,
2007). In pre-menopausal women, GnRH analogues are associated
with rapid bone loss when used in the setting of breast cancer or
endometriosis. It results in greater bone loss than is seen with
chemotherapy-induced ovarian failure, although some recovery occurs
after its cessation (Fogelman et al., 2003).
The reproductive medicine specialist and gynaecologist may be
involved in diagnosing and managing reduced bone density or osteo-
porosis following breast cancer. Lifestyle guidance on calcium intake,
exercise and avoidance of bone toxins, such as smoking and excessive
alcohol, is important (Sambrook and Eisman, 2000). Bisphosphonates
may minimize the bone loss associated with AI use. Zoledronic acid
4 mg every 6 months effectively inhibited bone loss in breast cancer
patients using AIs and GnRH agonists (Gnant et al., 2007). The effect
on fracture reduction in breast cancer patients is not yet known. The
available data do not support fracture prevention with bisphosponates
in women with a femoral neck T score above –2.5 and no prevalent
fracture. Indeed, among women with T score . –2.0, more wrist
fractures were reported in the ‘FIT’ study in the Alendronate group
versus placebo (RH ¼ 1.9; 95% CI ¼ 1.0–4.0) (Cummings et al.,
1998). The use of bisphosphonates for fracture prevention should
depend on absolute risk of fracture (Prince, 2001).
Conclusions
Increasing numbers of breast cancer survivors are presenting to repro-
ductive medicine specialists and their gynaecologists with symptoms
secondary to breast cancer treatments and queries regarding
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younger women who prefer greater involvement in treatment
decision-making and their needs for information may differ from
older women (Degner et al., 1997). In general, patients who are
better informed experience greater emotional, social and physical
well-being (Fallowﬁeld et al., 1994), better clinical outcomes, quality
of life (Fallowﬁeld et al., 1994) and satisfaction with care (Weiss
et al., 1996). Timing of information is important. Fertility discussions
need to be prioritized and considered soon after diagnosis and
before chemotherapy. Interventions such as IVF or ovarian tissue
freezing should be discussed in detail in relation to the patient’s per-
sonal and medical circumstances. Predicting fertility following che-
motherapy for breast cancer remains problematic, and more
sensitive indices of ovarian function as well as longitudinal data regard-
ing subsequent infertility, pregnancy and pregnancy outcome are
needed in order to better inform women about the consequences
of chemotherapy and the likelihood of a subsequent pregnancy.
Current evidence suggests that pregnancy does not appear to be det-
rimental following breast cancer, but individualized counselling regard-
ing prognosis and risk relapse based on their age and pathological
features of the cancer is required before patients can make informed
decisions regarding future childbearing.
The management of menopausal symptoms following breast cancer
is a particular challenge. There is a growing literature on safe and effec-
tive non-hormonal treatments for hot ﬂushes. However, other
common menopausal symptoms such as vaginal dryness and sexual
dysfunction should not be overlooked and are likely to require
additional management. There is a growing recognition of the import-
ance of developing a ‘survivorship care plan’ to coordinate care of
women with a prior history of breast cancer and to address and
prevent the long-term side effects and consequences of adjuvant
therapies (Ganz and Hahn, 2008). This is best done by a multi-
disciplinary team, of which the reproductive medicine specialist and
gynaecologist are integral members.
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